Navigation Links
Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Date:8/19/2007

NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Xenomics, Inc. (the "Company") (Pink Sheets: XNOM; FWB: XE7) a developer of next-generation medical DNA diagnostic technologies, announced today that its first diagnostic test developed for stratification of patients with Acute Myeloid Leukemia (AML) has been implemented at CLIA approved BRT Laboratories Inc. in Baltimore, Maryland, and is available for clinicians.

AML is the most common form of acute leukemia with about 13,400 new cases expected in 2007 in the USA and a similar number in Europe. Early detection of AML subtypes is important for development of a treatment strategy. The new test is based on a recent discovery of Drs. Falini and Mecucci at the Institute of Hematology at the University of Perugia in Italy that mutations in a nucleophosmin (NPM1) gene are characteristic of 30-40% of the cases of AML. NPM1 is a protein involved in regulation of ribosome biogenesis, cell division, cell death, and other important processes. Xenomics has obtained an exclusive license for the invention and developed a test that detects all 45 known mutations of NPM1 in a single reaction. The results will help physicians with prognosis, therapy, and monitoring of the disease. Stratification of AML patients is also necessary for anti-AML drug clinical trials.

"We are glad to work with Xenomics on AML diagnostics and to add this test to our repertoire of genetic tests" commented Antonette Allen, Clinical Service Manager of BRT Laboratories. "We believe that the NPM1 diagnostic test will not only help hematologists in the treatment of the disease but also in developing a test for monitoring the disease and patient response to anti-tumor therapy".

About Xenomics, Inc.

Xenomics is a molecular diagnostics company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of application
'/>"/>

SOURCE Xenomics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: VTAE ).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On February 27, 2015, the Company announced ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... a pre-clinical study published in the Proceedings ... www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ® ... checkpoint inhibitor), suppression of tumor growth was enhanced ... treating certain hematologic cancers and solid tumors with ...
(Date:2/27/2015)... 27, 2015  Acsis Inc., the market leader for ... today that John DiPalo , Acsis, Chief Strategy ... Demand Chain Executive 2015 Provider Pro to Know. ... initiatives to help prepare their companies, and customers, supply ... This year,s list of Provider Pros to Know is ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... (DSMB) Authorizes Enrollment of Cervical ... Authorized Dosage Level, HOPKINTON, Mass., Sept. 24 ... independent Data,Safety Monitoring Board (DSMB) has unanimously authorized expanding ... injury (SCI) to,allow subjects with cervical SCI to be ...
... Enrollment Ahead of Schedule with Completion Expected Q2 ... Inc. (Nasdaq: ALTH ) today announced the ... safety data from the,Company,s pivotal Phase 2 PROPEL ... refractory peripheral T-cell lymphoma (PTCL). Results of,the interim ...
Cached Medicine Technology:Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 2Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 3Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 4Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 5Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5
(Date:2/27/2015)... 27, 2015 The V Foundation for ... funding organizations, is excited to announce numerous promotions taking ... and many long-standing partnerships highlight The V Foundation’s significant ... expanding ways for all to get involved. Awarding ... cancer research, The V Foundation has funded more than ...
(Date:2/27/2015)... February 27, 2015 The federal court ... that allege use of the statin medication can increase ... issued a new order pertaining discovery in the cases ... Liebhard LLP comments. The Order, which was issued in ... February 25th, directs the parties to schedule certain witness ...
(Date:2/27/2015)... 27, 2015 Royal River Natural Foods, a ... new study that found adults who got the most magnesium ... diabetes compared to those who got the least magnesium, with ... , The report is part of the March 2015 issue ... River Natural Foods publishes free each month for the Freeport ...
(Date:2/27/2015)... Dr. Andrew Campbell, one of the ... to announce the expansion of Quintessa Aesthetic Center with ... has begun seeing patients on February 18, 2015. , ... offer a variety of state-of-the-art surgical and non-surgical ... laser peels, chemical peels, microdermabrasion, ProFractional Laser, Broad Band ...
(Date:2/27/2015)... According to court documents, Donna Pirolli was a ... and underwent a procedure during which a duodenoscope was ... the duodenoscope allegedly had not been properly cleaned, Donna ... (CRE). , A lawsuit has been proceeding ... of Ms. Pirolli alleging that Lutheran General Hospital was ...
Breaking Medicine News(10 mins):Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2
... at Wake Forest University School of Medicine reveals that many ... immediate medical needs of a student or employee who suffers ... to support a new statewide program to place automated external ... to appear in the May/June 2009 issue of the ...
... (SIS) unveils SIS Trax, a tissue management solution that ... for hospitals to standardize their processes for acquiring, receiving, ... solution to be fully integrated with a perioperative information ... enables hospitals to improve patient safety, optimize revenue, reduce ...
... Conference Vice President for Public Policy Paul A. ... executive order to be issued by President Obama ... cell research:"President Obama,s executive order regrettably places ideology ... advancements. There are endless studies and stories ...
... Connectivity to be Presented at HIMSS09LOS ANGELES, ... (OTC Bulletin Board: FVRL), which through its ... provides Web-based consumer-controlled Personal Health Records ("PHRs") ... box storage solutions ( www.myesafedepositbox.com ), announced ...
... Chef Cat Cora ( www.catcoracooks.com ), ... Chef of Bon Appetit is excited to announce she ... her first pregnancy and the fourth child for the Cora family. ... deliver their third child, also a boy, in April. "Jennifer and ...
... Seen in Patient Delays and Unnecessary StaysCOLLEGE PARK, Md., March ... Maryland,s Robert H. Smith School of Business put a ... hospitals at $12 billion per year. The research, newly released ... is the first to quantify the economic impact of a ...
Cached Medicine News:Health News:Study prompts new mandate for N.C. high schools 2Health News:Study prompts new mandate for N.C. high schools 3Health News:SIS Trax Unveiled as First Fully Integrated Tissue Management Solution 2Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 2Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 3Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 4Health News:Celebrity Chef Cat Cora Announces First Pregnancy 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 3
... surgery and other types of refractive surgery. ... stromal bed. Flattened tip provides easy insertion ... flap edge. Multiple ports provide multi-directional irrigation. ... 7mm from end. Two .15mm ports 2mm, ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 21G x 7/8in (.80 ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 23G x 7/8 in (.60 x 22mm). .3mm end port. Olive shape tip is 2mm long x 1mm w...
For injecting anesthetics into the muscle cone. 25G x 1 1/2 in (.50 x 38mm)...
Medicine Products: